Tollys
  • About Us
    • Company
    • Board of Directors
    • Management
    • Scientific Advisory Board
  • Science
    • Immuno-oncology
    • TLR3 Science
    • Publications
  • Product
    • TL-532
    • Intellectual property
  • Pipeline
    • Bladder Cancer
    • TLR3+ Cancers
  • News
  • Contact
Select Page

Tollys receives over €1.5 million deep tech financing from Bpifrance

by SmallStories | Jul 6, 2020 | News

Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.

Tollys closes Series A financing of €2.3 million

by SmallStories | May 25, 2020 | News

Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.

Recent Posts

  • Tollys receives over €1.5 million deep tech financing from Bpifrance
  • Tollys closes Series A financing of €2.3 million
  • Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma
  • Corrigendum to “Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis” [J Hepatol 71 (2019) 763-772]
  • Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Recent Comments

    Archives

    • July 2020
    • May 2020
    • December 2019
    • November 2019
    • August 2018
    • June 2016
    • January 2015
    • September 2012
    • March 2011
    • December 2007
    • August 2007
    • April 2006
    • September 1991
    • July 1980

    Categories

    • News
    • Publications

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Design by Small Stories ©2019